Neurology

Cat. No.

AT0584

CAS No.

1788032-39-2

Gosuranemab

Synonyms: BMS-986168; IPN007; BIIB092

Gosuranemab (BMS-986168) is a humanized IgG4 monoclonal antibody specifically designed to target and bind to the N-terminal residues 15-22 of the tau protein in humans. This antibody is primarily explored for its potential applications in Alzheimer’s disease research, focusing on its ability to interact with tau, a protein implicated in the pathogenesis of neurodegenerative disorders.

Cat. No.

AT0661

CAS No.

2850367-41-6

Amlenetug

Amlenetug is a human monoclonal antibody of the IgG1κ subtype that specifically targets SNCA (α-synuclein). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control. This antibody is ideal for research focusing on the role of SNCA in neurodegenerative disorders such as Parkinson's disease.

Cat. No.

AT0696

CAS No.

2966023-63-0

ARGX-119

ARGX-119 is a pioneering humanized agonist monoclonal antibody that selectively targets muscle-specific kinase (MuSK). This antibody is particularly useful for the investigation of neuromuscular diseases, providing a critical tool for understanding the pathophysiology and potential therapeutic interventions in these disorders. For isotype control purposes, researchers should use Human IgG1 lambda1, Isotype Control, which serves as a standard for experimental consistency and validation.

Cat. No.

AT0719

CAS No.

1578199-75-3

Galcanezumab

Synonyms: LY 2951742

Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody designed to specifically target and neutralize the calcitonin gene-related peptide (CGRP) ligand. This antibody is utilized extensively in research focused on migraine and cluster headaches, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these conditions.

Cat. No.

AT0725

CAS No.

2414866-63-8

Anselamimab

Synonyms: CAEL-101

Anselamimab (CAEL-101) is a humanized IgG1-κ monoclonal antibody designed to specifically target serum amyloid A1 (SAA1) amyloid fibrils. This antibody binds with high affinity to the SAA1 amyloid fibrils, a key pathological component in amyloidosis disorders, thereby offering potential for therapeutic intervention and disease-modifying effects in amyloid-related diseases. Anselamimab is utilized primarily in research focused on the pathogenesis and treatment of amyloidosis, making it a valuable tool for both basic research and clinical development studies.

Cat. No.

AT0740

CAS No.

2171034-70-9

Relfovetmab

Relfovetmab is a monoclonal antibody that targets nerve growth factor (NGF). This antibody is specifically designed to bind and inhibit NGF, a key molecule involved in the regulation of pain and inflammation. Relfovetmab's mechanism of action makes it a valuable tool for research into pain management and the biological pathways of inflammation.

Cat. No.

AT0763

CAS No.

2096513-89-0

Tilavonemab

Synonyms: ABBV-8E12; C2N-8E12

Tilavonemab (ABBV-8E12) is a humanized monoclonal antibody designed to target and neutralize extracellular pathological tau protein aggregates. It specifically binds to the N-terminal 25-30 amino acid residues of the tau protein. This interaction inhibits the uptake of tau aggregates by human and mouse neurons, mitigates brain volume loss, decelerates the progression of tau pathology, and enhances cognitive functions in transgenic mice models expressing mutant human tau. Tilavonemab is primarily utilized in research focused on Alzheimer's disease, offering significant insights into the mechanisms of tau-related neurodegeneration and potential therapeutic interventions.

Cat. No.

AT0831

CAS No.

648895-38-9

Bapineuzumab

Bapineuzumab is a monoclonal antibody targeting the β-amyloid protein (APP), specifically designed for Alzheimer’s disease research. This antibody binds to the β-amyloid plaques, which are a hallmark of Alzheimer’s pathology, making it an essential tool for studies focused on disease mechanisms and potential therapeutic interventions.

Cat. No.

AT0832

CAS No.

1190239-42-9

Fasinumab

Fasinumab is a human IgG4 monoclonal antibody specifically targeting nerve growth factor (NGF). This antibody is utilized in research focused on acute sciatica and knee osteoarthritis, providing a valuable tool for studies investigating the role of NGF in pain and inflammation associated with these conditions.

Cat. No.

AT0897

CAS No.

902141-80-4

Fulranumab

Fulranumab is a human IgG2 monoclonal antibody that targets nerve growth factor (NGF), making it a valuable tool for pain research. This antibody binds specifically to NGF, a key mediator in the development and sensation of pain, potentially inhibiting its biological activity and providing insights into pain management mechanisms. Fulranumab is suitable for various experimental applications to explore the role of NGF in pain pathways and therapeutic interventions.

Cat. No.

AT0953

CAS No.

2447755-72-6

Izenivetmab

Synonyms: ZTS-00075623

Izenivetmab (ZTS-00075623) is a caninized monoclonal antibody of the IgG2κ isotype, specifically targeting nerve growth factor beta (NGFB). This therapeutic antibody is designed for use in canine models, facilitating the study of NGFB's role in various biological processes and potential therapeutic interventions.

Cat. No.

AT0989

CAS No.

955085-14-0

Solanezumab

Synonyms: LY-2062430

Solanezumab is a humanized monoclonal IgG1 antibody that specifically targets the mid-domain of the amyloid-β (Aβ) peptide. This antibody is designed for use in Alzheimer’s disease research, focusing on the pathological mechanisms associated with Aβ aggregation and plaque formation. Solanezumab's specificity and mode of action make it a valuable tool for investigating the potential therapeutic interventions in Alzheimer’s disease pathology.

Cat. No.

AT1022

CAS No.

1931944-80-7

Donanemab

Synonyms: LY3002813

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody that targets a specific N-terminal pyroglutamate amyloid beta (Aβ) epitope. This antibody is designed for use in research focused on early-stage Alzheimer's disease, providing a critical tool for studies aimed at understanding and potentially intervening in the disease's pathogenesis.

Cat. No.

AT1044

CAS No.

2097151-87-4

Pepinemab

Synonyms: VX 15/2503

Pepinemab (VX 15/2503) is a human monoclonal antibody designed to target and neutralize SEMA4D (Signaling Protein 4D), also recognized as CD100. SEMA4D is a critical regulator of neuronal development and is implicated in a range of cellular processes. By inhibiting the activity of SEMA4D, Pepinemab serves as a valuable tool for the investigation of neurodegenerative disorders, including Alzheimer's disease. This antibody is specifically engineered for research applications focused on elucidating the role of SEMA4D in disease pathogenesis and cellular function.

Cat. No.

AT1078

CAS No.

1608108-91-3

Birtamimab

Synonyms: NEOD001

Birtamimab (NEOD001) is an investigational monoclonal antibody designed to specifically and selectively target and clear amyloid deposits. This antibody is primarily utilized in research focused on light chain amyloidosis, providing a targeted approach to study the pathological mechanisms and potential therapeutic interventions for this condition.

Cat. No.

AT1118

CAS No.

1226761-65-4

Atinumab (NG-101)

Synonyms: NG-101

Atinumab (NG-101) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets RTN4/NOGO, a protein implicated in the inhibition of neuronal growth and regeneration. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 146.62 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT1132

Anti-MUSK Antibody

Cat. No.

AT1136

CAS No.

1662664-56-3

Dezamizumab

Synonyms: GSK 2398852; Anti-Serum Amyloid P/SAP Reference Antibody (dezamizumab

Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal IgG1 antibody targeting the serum amyloid P component (SAP), exhibiting potential anti-amyloid activity. This antibody facilitates the immunotherapeutic clearance of amyloid deposits. It is primarily utilized in the study of Amyloid light-chain (AL) amyloidosis, providing a valuable tool for research into the pathogenesis and treatment of this condition.

Cat. No.

AT1155

CAS No.

1384260-65-4

Aducanumab

Synonyms: BIIB037

Aducanumab (BIIB037) is a human monoclonal antibody designed to selectively target aggregated forms of amyloid-beta (Aβ), a key pathological marker in Alzheimer’s disease (AD). Demonstrating effective penetration into brain tissue, Aducanumab is extensively utilized in the research of Alzheimer's disease mechanisms and potential therapies. This antibody is pivotal for studies focusing on the pathogenesis and treatment strategies of AD, providing essential insights into amyloid-beta dynamics and clearance in neural environments.

Cat. No.

AT1165

CAS No.

1708936-80-4

Frunevetmab

Synonyms: NV-02

Frunevetmab (NV-02) is a felinized monoclonal antibody targeting nerve growth factor (NGF) with a dissociation constant (Kd) of 20 pM, indicating high affinity for its antigen. This antibody has been shown to effectively reduce osteoarthritis-related pain in feline models, making it a valuable tool for research into pain management and degenerative joint diseases in cats.

Cat. No.

AT1185

CAS No.

880266-57-9

Tanezumab

Synonyms: RN-624; PF 4383119

Tanezumab (RN-624) is a humanized monoclonal antibody that exhibits high affinity and specificity for nerve growth factor (NGF). By effectively blocking the interaction of NGF with its receptors, p75 and TrkA, Tanezumab modulates pain signaling pathways in the peripheral nervous system. This antibody is utilized extensively in research focused on both acute and chronic pain conditions, including osteoarthritis, knee pain, neuralgia, and post-herpetic neuralgia, providing a valuable tool for the study of pain mechanisms and therapeutic interventions.

Cat. No.

AT1233

CAS No.

2171034-69-6

Bedinvetmab

Synonyms: ZTS-00508841

Bedinvetmab (ZTS-00508841) is a canine-specific monoclonal antibody designed to target nerve growth factor (NGF). By inhibiting the interaction of NGF with its receptors, tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR), Bedinvetmab effectively modulates pain signaling pathways. This antibody is particularly useful for research into the management of osteoarthritis pain in canine models, providing a valuable tool for understanding and potentially mitigating pain mechanisms in dogs.

Cat. No.

AT1254

CAS No.

2690265-18-8

Etalanetug

Etalanetug is a humanized IgG1κ monoclonal antibody that selectively targets microtubule-associated protein tau (MAPT). For control experiments, it is recommended to use Human IgG1 kappa as the isotype control. This antibody is designed for the specific detection and study of MAPT's role in various biological processes, making it an essential tool for research in neurodegenerative diseases and other tauopathies.

Cat. No.

AT1276

CAS No.

2379805-59-9

Unasnemab

Synonyms: MT-3921; rH116A3

Unasnemab (MT-3921), a humanized IgG1 monoclonal antibody, specifically targets and binds to repulsive guidance molecule A (RGMa). This interaction facilitates the improvement of locomotor functions and promotes neuroregeneration. Unasnemab is primarily utilized in research focused on spinal cord injuries, offering significant insights into therapeutic strategies and recovery mechanisms.

Cat. No.

AT1304

CAS No.

2019133-28-7

Zagotenemab

Synonyms: LY33003560

Zagotenemab (LY3303560) is a humanized monoclonal antibody designed to selectively bind to and neutralize tau protein deposits in the brain. This antibody is specifically developed for use in research related to Alzheimer's disease, providing a critical tool for investigating the role of tau in neurodegeneration and assessing potential therapeutic strategies.